Lineage Cell Therapeutics, Inc. Shareholders' Equity
Lineage Cell Therapeutics, Inc. (LCTX) had Shareholders' Equity of $60.92 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $60.92M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $53.88M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $44.55M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $22.04M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $60.92M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $53.88M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $44.55M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $22.04M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $48.38M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $79.03M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $78.38M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $66.19M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $68.30M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $72.40M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $63.42M 10-K · filed 2025-03-10 | |
| 2023-09-30 | $68.12M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $72.67M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $70.45M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $73.34M 10-K · filed 2024-03-07 | |
| 2022-09-30 | $78.95M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $82.85M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $86.55M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $92.22M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $120.71M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $124.71M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $117.67M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $96.20M 10-K · filed 2022-03-10 | |
| 2020-09-30 | $91.27M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $99.44M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $106.50M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $112.96M 10-K · filed 2021-03-11 | |
| 2019-09-30 | $117.16M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $133.39M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $161.24M 10-Q · filed 2020-05-07 | $162.84M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $92.25M 10-Q · filed 2020-05-07 | $93.84M 10-K · filed 2019-03-14 |
| 2018-09-30 | $171.13M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $100.98M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $99.97M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $162.64M 10-K · filed 2019-03-14 | |
| 2017-09-30 | $198.29M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $176.13M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $187.37M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $117.93M 10-K · filed 2018-03-15 | |
| 2016-09-30 | $119.39M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $85.74M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $10.85M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $25.82M 10-K · filed 2017-03-16 | $26.89M 10-K · filed 2016-03-15 |
| 2015-09-30 | $13.04M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $16.98M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $26.25M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $36.46M 10-K · filed 2016-03-15 | $36.46M 10-K · filed 2015-03-11 |
| 2014-09-30 | $10.98M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $17.91M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $19.24M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $14.80M 10-K · filed 2015-03-11 | |
| 2013-09-30 | $12.94M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $20.92M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $15.84M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $9.58M 10-K · filed 2014-03-17 | |
| 2012-09-30 | $16.94M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $23.18M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $24.20M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $28.65M 10-K · filed 2013-03-18 | |
| 2011-09-30 | $33.62M 10-Q · filed 2011-11-08 | |
| 2011-06-30 | $36.14M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $38.17M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |